Form 4: Versant Venture Capital VI, L.P. Reports Changes in Beneficial Ownership of Monte Rosa Therapeutics, Inc. (GLUE)

Versant Venture Capital VI, L.P. files Form 4 detailing sales and distributions of Monte Rosa Therapeutics, Inc. common stock.

Summary

• On October 28 and 29, 2024, Versant Venture Capital VI, L.P. and related entities engaged in transactions involving Monte Rosa Therapeutics, Inc. (GLUE) common stock.
• These transactions included sales of common stock at weighted average prices ranging from $9.50 to $10.00 on October 28 and from $8.36 to $9.50 on October 29.
• Additionally, there were pro-rata distributions of shares to partners and changes in the form of ownership due to in-kind distributions of common stock for no consideration.
• The reporting entities include Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP, L.P., and Versant Vantage I GP-GP, LLC.
• These entities may be deemed to share voting, investment, and dispositive power over the shares held by Versant VI and Versant Vantage I, but disclaim beneficial ownership except to the extent of their pecuniary interests.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions without expressing positive or negative views on the company's prospects. It's a routine filing.

Industry Context

This filing reflects ongoing transactions by a major shareholder, Versant Venture Capital, in Monte Rosa Therapeutics. Such transactions are common and can be driven by fund lifecycle considerations, portfolio rebalancing, or strategic decisions regarding the investment.

Comparison to Industry Standards

• Form 4 filings are standard practice for insiders and major shareholders, like Versant Venture Capital, to report changes in their ownership positions.
• The reported transactions are typical for venture capital firms managing their investments in publicly traded companies.
• Similar filings can be observed for other biotech companies with significant venture capital backing, such as Flagship Pioneering's involvement with Moderna or Third Rock Ventures' investments in various biotech startups.

Stakeholder Impact

• The sales of shares by Versant Venture Capital may have a minor impact on the stock price of Monte Rosa Therapeutics.
• The pro-rata distributions to partners do not directly impact the company's operations or financial position.

Key Dates